Cargando…
Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece [Corrigendum]
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365738/ https://www.ncbi.nlm.nih.gov/pubmed/25834459 http://dx.doi.org/10.2147/CEOR.S82058 |
Ejemplares similares
-
Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece
por: Fragoulakis, Vassilis, et al.
Publicado: (2015) -
Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential [Corrigendum]
Publicado: (2019) -
Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
Publicado: (2014) -
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management [Corrigendum]
Publicado: (2022) -
Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2021)